Our analysis of GAD65Ab in patients with T2D in the GRADE study revealed GAD65Ab patterns that differed significantly from those observed in patients with T1D or LADA, showing low GAD65Ab titers, lack of GAD65Ab epitope specificities characteristic for patients with T1D or LADA, and a wide range of GAD65Ab epitope-specific anti-Id levels, rather than a lack of GAD65Ab epitope-specific anti-Ids as found in patients diagnosed with T1D or LADA [16]. Here, IDS is linked to type 2 diabetes mellitus.